P54

PLASMA ENDOCAN LEVEL AND PROGNOSTIC SIGNIFICANCE IN BREAST CANCER PATIENTS

Ozturk Ates (Dr.Abdurrahman Yurtaslan Training and Research Hospital, Medical Oncology, Ankara, Turkey) Emre Gedik (Hacettepe University Cancer Institute, Basic Oncology, Ankara, Turkey) Veli Sunar (Hacettepe University Cancer Institute, Medical Oncology, Ankara) Mustafa Kadri Altundag (MKA Breast Cancer Clinic, Tepe Prime, Ankara)

Introduction - Purpose : Endocan, known as endothelial cell specific molecule (ESM), is a dermatan sulphate proteoglycan. It is a novel endothelial dysfunction marker, plasma levels of which have recently been shown to be elevated in some cancer types. The aim of this study is to examine the plasma endocan level and its prognostic significance in newly diagnosed breast cancer patients.

Methods - Tools : A total of 84 patients were enrolled the study. Ethical approval and informed consent were attained. Plasma endocan level was measured by specific enzyme-linked immunosorbent assay (ELİSA) kit.

Findings: Mean diagnostic age of patients were 52.5±13.3 (27-84), and 54.7% of the patients are postmenopausal. Demographic features of patients are seen in Table 1. At the time of diagnosis, 33 patients had stage 4 disease. Invasive ductal cancer (IDC) and invasive lobular cancer (ILC) constituted 76.2% and 3.2% of patients respectively. The median plasma endocan level was 619.9 (min 259.9-2813.2) ng/L and its level was significantly higher in metastatic breast cancer group compared to non-metastatic breast cancer group. According to molecular sub-type of breast cancer, there is not statistical difference in plasma endocan level, but its level was higher in patients with Her-2 amplified and TNBC (table 2). Median follow-up time is 11 (1-30) months. Event free survival (EFS) was 15 months in patients with plasma endocan level lower than 620, while it was 4 months in patients with serum endocan level greater than 620 (p=0.016) (figure 1). There was no difference between groups in terms of hypertension, age, Lymphovascular invasion (LVI), extra capsular extension (ECE), body mass index (BMI) and White blood cells (WBC), platelet count and plasma endocan level. When clinicopathological parameters were compared according to metastatic or non metastatic situation there were no significant difference. Only CEA and Ca15-3 levels were higher in metastatic group than non metastatic group (Table 3)

Discussion : Endocan is secreted from vascular endothelium by stimuli of inflammatory cytokines, and regulates cellular adhesion, migration and proliferation. Serum endocan level is known to increase in endothelial dysfunction situations such as sepsis, Chronic kidney disease and Diabetic proliferative retinopathy.Serum endocan level has been shown to increase in some cancers (such as gastric and ovarian cancer). Serum levels of which are shown positive correlation with in tumor recurrence and progression. It was used as a prognostic biomarker in some cancer types.We have shown that plasma endocan level is higher in metastatic group than non metastatic group by means of in this study. Also we found that patients with high plasma endocan levels were poor prognosis. According to the sub-type analysis, there was not statistical difference in plasma endocan levels but the level was higher in patients with Her-2 amplified breast cancer and TNBC. Further studies would be useful to assess endocan level as a prognostic factor in breast cancer.

Keywords: Endocan, Breast cancer, Prognosis

11 12 13	13 (15.5) 42 (50)
T3	
THE REPORT OF TAXABLE PARTY OF TAXABLE PARTY.	40 140 00
The state of the second s	13 (15.5)
T4	12 (14.3)
NO	26 (31)
N1	20 (23.8)
N2	17 (20.2)
N3	17(20.2)
itago	
Stage 1	10 (11.9)
Stage 2	21 (25)
Stage 3	20 (23.8)
Stage 4	33 (39.2)
Hormonal situation	
ER+	61 (72.6)
PR+	51 (60.7)
Hormone receptor Positive	63 (75)
Negative	ext 21 (25)
BMI	
<24.9	18 (21.4)
25-29.9	34 (40.5)
>30	32 (38.1)
Co-morbid disease	
DM	12 (14.3)
HT	25 (29.8)
Pathology	
IDC	64 (76.2)
Mix	3 (3.6)
Mucinous	13 (15.5)
Metaplastic	2 (2.4) 1 (1.2)
Neuroendocrine	1 (1.2)
Sub-type	1(1.4)
Luminal A	26 (31)
Luminal B	34 (40.5)
Her-2	11 (13.1)
TNBC	13 (15.5)
Age of diagnosis	
s40	15 (17.8)
40-49	19 (22.6)
50.50	23 (27.5)
80-69 >70	15 (21-4) 9 (10.7)

Patients Characteristics

Table 2


Parameters	n	Plasma endocan level	p
itage			
Stage 1-3	51	547.6	0.045
itage 4	33	695.3	
ab-type			
Luminal A	25	581	0.41
Luminal B	34	611	
Her-2	11	678	
TNBC	14	595	
M			
Yes	12	465	
No	72	681	0.007
нт			
Yes	25	542	a state
No	59	671	0.16
Menopausal situ. Premenopausal	34	673	
Premenopausal	4	1312	0.47
Postmenopausal	avte	602	
Grade	ext		
Grade1	42	581	222.00
Grade 2-3	41	683	0.2
BMI			
<24.9	18	774	
25-29.9	34 32	549 649	0.2
>30	34	049	
LVI		2022	
Yes	36 48	707.3 575.3	0.11
No	46	312.3	
ECE	25	756.6	0.09
Yes	25 59	585.6	Contraction of the local division of the loc
No	2.2	203.0	States and States
WBC >10.000	10	671	
<10.000	74	611	0.56
Age	60	690	and the second
-55	50 34	564	0.19

Association of serum endocan levels with clinical and pathological variables in breast cancer patients

Lable 3	2	2	Δ	h	ົລ	Т

	Metastatic	Non-metastatic	p
No of patients	33	51	
Age, year	51±12.4	53.1±13.9	0.65
BMI, kg/m ²	28.9±5.5	28.5±5.4	0.73
Presence of hypertension [n, (%)]	7 (21%)	18 (35%)	0.16
Presence of diabetes [n, (%)]	4 (12%)	8 (24%)	0.75
Menaupose [n, (%)] Premenauposel	Te 12 (36%)	22 (43%)	0.72
Postmenauposel	68(54%)	28 (54%)	and the second
LVI	16	20	0.27
CEA	0.8-3400 (2.6)	0.6-4.7 (1.3)	0.0001
Ca15-3	4.7-719 (23)	4.9-20.7 (12.3)	0.0001
Grade Grade 1	13 (39.4%)	29 (56.9%)	0.11
Grade 2-3	20 (60.6%)	22 (43.1%)	
Presence of estrogen receptor [n, (%)]	24 (72.7%)	37 (72.5%)	0.98
Presence of progesterone receptor [n, (%)]	20 (60.6%)	31 (60.8%)	0.98
Presence of Her2 [n, (%)]	9 (27.3%)	18 (35.3%)	0.44

Clinicopathological parameters according to the metastatic status



Kaplan-Meier curves for Event free survival (EFS) of serum endocan levels